BenevolentAI SPAC Presentation Deck

3 Precision medicine for more targeted drugs and clinical trials • Diseases are commonly defined by symptoms or location in the body. We take a different approach: find their underlying patient-specific molecular mechanisms or pathways and use from the start of our Target ID process • We detect subgroups of patients by applying machine learning approaches to mining multimodal patient level data at scale *** Multimodal Omics / Clinical Trial data KNOWLEDGE GRAPH (1) Based on Biomed Report 2021. Endotype Detection Target Prediction 艰 Biomarker ID Phase II trials with pre-selection biomarkers are >50% more likely to succeed (¹) A patient centric approach to drug discovery ✔ Pipelines are based on patient level data such as electronic health record data, biomarkers, genetic and omics data. ✓ Identify biomarkers and responder patients to design faster, more effective clinical trials and increase the probability of clinical success ✔ Genetic pipelines built for scale, ~1000x faster than traditional pipelines using over 1TB of genetic data with better experiment, cell line and tissue coverage than industry standard Benevolent 16

View entire presentation